Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA

Bibliography

• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide. 2013. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx [Last accessed 21 May 2015]
   Google Scholar
• Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60(5):277-300
   PubMed Web of Science ®Google Scholar
• Cleator SJ, Ahamed E, Coombes RC, et al. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer 2009;9(Suppl 1):S6-17
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25(1):118-45
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med 2001;344(11):783-92
   PubMed Web of Science ®Google Scholar
• Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Nat Cancer Inst 2014;106:5
   PubMed Web of Science ®Google Scholar
• Howlader N NA, Krapcho M, Garshell J, et al. SEER Cancer Statistics Review, 1975-2010. 2013 based on November 2012 SEER data submission, posted to the SEER web site. Available from: http://seer.cancer.gov/csr/1975_2010/ [Last accessed 20 May 2014]
   Google Scholar
• National Cancer Institute. SEER stat fact sheets: breast cancer. Available from: http://seer.cancer.gov/statfacts/html/breast.html [Last accessed 15 September 2015]
   Google Scholar
• Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic patterns and their prognosis. South Med J 1988;81(9):1109-12
   PubMed Web of Science ®Google Scholar
• Wyld L, Gutteridge E, Pinder SE, et al. Prognostic factors for patients with hepatic metastases from breast cancer. Br J cancer 2003;89(2):284-90
   PubMed Web of Science ®Google Scholar
• Sofocleous CT, Nascimento RG, Gonen M, et al. Radiofrequency ablation in the management of liver metastases from breast cancer. Am J Roentgenol 2007;189(4):883-9
   PubMed Web of Science ®Google Scholar
• Khanfir A, Lahiani F, Bouzguenda R, et al. Prognostic factors and survival in metastatic breast cancer: A single institution experience. Rep Pract Oncol Radiother 2013;18(3):127-32
   Google Scholar
• Kitagawa D, Horiguchi S, Yamashita T, et al. Comparison of outcomes between women with de novo stage IV and relapsed breast cancer. J Nippon Med Sch 2014;81(3):139-47
   PubMed Web of Science ®Google Scholar
• Duan XF, Dong NN, Zhang T, et al. The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer. Int J Clin Oncol 2013;18(1):26-32
   PubMed Web of Science ®Google Scholar
• Ge QD, Lv N, Kong YN, et al. Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases. Asian Pac J Cancer Prev 2012;13(10):5081-6
   PubMed Web of Science ®Google Scholar
• Savci-Heijink CD, Halfwerk H, Hooijer GK, et al. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat 2015;150(3):547-57
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer v.3.2014. 2014. Available from: http://www.nccn.com [Last accessed 15 September 2014]
   Google Scholar
• Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012;21(3):242-52
   PubMed Web of Science ®Google Scholar
• Cardoso F, Harbeck N, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii11-19
   PubMed Web of Science ®Google Scholar
• Roche H, Vahdat LT. Treatment of metastatic breast cancer: second line and beyond. Ann Oncol 2011;22(5):1000-10
   PubMed Web of Science ®Google Scholar
• Swallow E, Zhang J, Thomason D, et al. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012. Curr Med Res Opin 2014;30(8):1537-45
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Eng J Med 2012;366(6):520-9
   PubMed Web of Science ®Google Scholar
• Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 2013;30(10):870-84
   PubMed Web of Science ®Google Scholar
• Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012;30(22):2718-24
   PubMed Web of Science ®Google Scholar
• Campone M, Bachelot T, Gnant M, et al. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. Eur J Cancer 2013;49(12):2621-32
   PubMed Web of Science ®Google Scholar
• Er O, Frye DK, Kau SW, et al. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J 2008;14(1):62-8
   PubMed Web of Science ®Google Scholar
• Bachelot T, McCool R, Duffy S, et al. Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis. Breast Cancer Res Treat 2014;143(1):125-33
   PubMed Web of Science ®Google Scholar
• Pouget M, Planchat E, Abrial C, et al. Everolimus plus hormonotherapy (HT) induces survival gain in late metastatic breast cancer (MBC) after progression: Could this line be better than a late new chemotherapy (CT) line? abstract # 401P. Eur Soc Med Oncol 2014. Available from: https://www.webges.com/cslide/library/esmo/browse/search/oRS#9faC02xU [Last accessed 20 May 2015]
   Google Scholar
• Cope S, Zhang J, Saletan S, et al. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med 2014;12:93
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Hozaeel W, Tauchert FK, et al. The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax). Ann Oncol 2015;26(6):1244-8
   PubMed Web of Science ®Google Scholar
• Ono M, Ogilvie JM, Wilson JS, et al. A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer. Front Oncol 2015;5:59
   PubMed Web of Science ®Google Scholar